Write your message
Volume 4, Issue 2 (Spring 2019)                   J Obstet Gynecol Cancer Res 2019, 4(2): 57-61 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Karimi Zarchi M, Mehdizadeh Kashi A, Allahqoli L, Sadat Tabatabai R, Shamsi F, Hashemian Asl N. The Recurrence and 5-Year Survival Rates in Patients with Borderline Ovarian Tumors in Yazd from 2006 to 2016. J Obstet Gynecol Cancer Res. 2019; 4 (2) :57-61
URL: http://jogcr.com/article-1-223-en.html
1- Endometriosis Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran
Endometriosis Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran , etemad80@gmail.com
Abstract:   (361 Views)

 Background & Objective: This study investigated the recurrence and survival rates of patients with borderline ovarian tumors in Yazd in the last 10 years.
 Materials & Methods: This census survival study was performed on 24 patients with borderline ovarian tumors who referred to hospitals affiliated to Yazd University of Medical Sciences from 2006 to 2016. A data collection checklist was used as a measurement tool and was completed by the researcher by reviewing the subjects’ medical records. The questionnaire included age, infertility, the number of delivery, contraceptive use, body mass index, time of diagnosis, time to start the treatment, whether alive or not, stage of the disease, the type of pathology, the type of surgery, and postoperative treatment. Data was analyzed by SPSS 16 using descriptive statistics.
 Results: The mean age of these 24 patients was 33.58±10.61 and the mean recurrence time was 14±2 months. Sixteen (66.7%) patients had serous tumors and 8 (33.3%) patients had mucinous tumors. Among them, 18 (75%) patients underwent a hysterectomy, 2 (8.3%) patients underwent an oophorectomy and 4 (16.7%) patients underwent both total abdominal hysterectomy (TAH) and oophorectomy. Of the 24 studied patients, 4 patients (16.7%) received medicinal treatment (clomiphene citrate, HCG, HMG) after surgery. Three patients experienced recurrences, all in the contralateral ovary.
 Conclusion: The recurrence time of epithelial borderline ovarian tumor was 14±2 months. There was no significant relationship between postoperative medicinal treatment and the recurrence rate.

Full-Text [PDF 400 kb]   (119 Downloads) |   |   Full-Text (HTML)  (83 Views)  

✅ The recurrence time of epithelial borderline ovarian tumor was 14±2 months. There was no significant relationship between postoperative medicinal treatment and the recurrence rate.


Systematic Review: Original Research | Subject: Gynecology Oncology
Received: 2019/09/18 | Accepted: 2019/11/10 | Published: 2019/12/29

References
1. Lalwani N, Prasad SR, Vikram R, Shanbhogue AK, Huettner PC, Fasih N. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment. Radiographics 2011; 31(3): 625-46. [DOI:10.1148/rg.313105066] [PMID] [DOI:10.1148/rg.313105066] [PMID]
2. Anfinan, N., Sait, K., Ghatage, P., Nation, J. & Chu, P. 2011. Ten years experience in the management of borderline ovarian tumors at Tom Baker Cancer Centre. Archives of gynecology and obstetrics, 284, 731-735. [DOI:10.1007/s00404-010-1713-9] [PMID] [DOI:10.1007/s00404-010-1713-9] [PMID]
3. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics. CA Cancer J Clin 2012; 62(1): 10-29. [DOI:10.3322/caac.20138] [PMID] [DOI:10.3322/caac.20138] [PMID]
4. Kanat-pektas, M., Ozat, M., Gungor, T., Dikici, T., Yilmaz, B. & Mollamahmutoglu, L. 2011. Fertility outcome after conservative surgery for borderline ovarian tumors: a single center experience. Archives of gynecology and obstetrics, 284, 1253-1258. [DOI:10.1007/s00404-010-1804-7] [PMID] [DOI:10.1007/s00404-010-1804-7] [PMID]
5. Rauh-Hain JA, Krivak TC, del Carmen MG, Olawaiye AB. Ovarian cancer screening and early detection in the general population. Reviews in obstetrics and gynecology. 2011;4(1):15.
6. Sanci M, Gultekin E, Cingillioglu B, Gultekin OE, Ozvural S, Emirdar V, Yildirim Y. Second primary cancers following borderline ovarian tumors. Archives of gynecology and obstetrics. 2011 Jun 1;283(6):1391-6. [DOI:10.1007/s00404-010-1585-z] [PMID] [DOI:10.1007/s00404-010-1585-z] [PMID]
7. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer biology & medicine. 2017 Feb;14(1):9.
8. Fischerova D, Zikan M, Dundr P, Cibula D. Diagnosis, treatment, and follow-up of borderline ovarian tumors. The oncologist. 2012;17(12):1515-33. [DOI:10.1634/theoncologist.2012-0139] [PMID] [PMCID] [DOI:10.1634/theoncologist.2012-0139] [PMID] [PMCID]
9. Seong SJ, Kim DH, Kim MK, Song T. Controversies in borderline ovarian tumors. Journal of gynecologic oncology. 2015;26(4):343-9. [DOI:10.3802/jgo.2015.26.4.343] [PMID] [PMCID] [DOI:10.3802/jgo.2015.26.4.343] [PMID] [PMCID]
10. Rauh-Hain JA, Krivak TC, Del Carmen MG, Olawaiye AB. Ovarian cancer screening and early detection in the general population. Reviews in obstetrics & gynecology. 2011;4(1):15-21.
11. Fischerova D, Zikan M, Dundr P, Cibula D. Diagnosis, treatment, and follow-up of borderline ovarian tumors. The oncologist. 2012 Dec 1;17(12):1515-33. [DOI:10.1634/theoncologist.2012-0139] [PMID] [PMCID] [DOI:10.1634/theoncologist.2012-0139] [PMID] [PMCID]
12. Abascal-Saiz A, Sotillo-Mallo L, De Santiago J, Zapardiel I. Management of borderline ovarian tumours: a comprehensive review of the literature. ecancermedicalscience. 2014;8.
13. Patrono MG, Minig L, Diaz-Padilla I, Romero N, Moreno JF, Garcia-Donas J. Borderline tumours of the ovary, current controversies regarding their diagnosis and treatment. Ecancermedicalscience. 2013;7.
14. Loizzi V, Selvaggi L, Leone L, Latorre D, Scardigno D, Magazzino F, Cormio G. Borderline epithelial tumors of the ovary: Experience of 55 patients. Oncology letters. 2015 Feb 1;9(2):912-4. [DOI:10.3892/ol.2014.2758] [PMID] [PMCID] [DOI:10.3892/ol.2014.2758] [PMID] [PMCID]
15. Romeo M, Pons F, Barretina P, Radua J. Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor. World journal of surgical oncology. 2013 Dec;11(1):1215. [DOI:10.1186/1477-7819-11-13] [PMID] [PMCID] [DOI:10.1186/1477-7819-11-13] [PMID] [PMCID]
16. Yasmeen S, Hannan A, Sheikh F, Syed AA, Siddiqui N. Borderline tumors of the ovary: A clinicopathological study. Pakistan journal of medical sciences. 2017 Mar;33(2): 369. [DOI:10.12669/pjms.332.11847] [DOI:10.12669/pjms.332.11847]
17. Morris RT, Gershenson DM, Silva EG, Follen M, Morris M, Wharton JT. Outcome and reproductive function after conservative surgery for borderline ovarian tumors. Obstetrics & Gynecology. 2000 Apr 1;95(4):541-7. [DOI:10.1097/00006250-200004000-00012] [PMID] [DOI:10.1097/00006250-200004000-00012] [PMID]
18. Auer K, Bachmayr-Heyda A, Aust S, Sukhbaatar N, Reiner AT, Grimm C, Horvat R, Zeillinger R, Pils D. Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome. Oncotarget. 2015 Jul 10;6(19):17261. [DOI:10.18632/oncotarget.3746] [PMID] [PMCID] [DOI:10.18632/oncotarget.3746] [PMID] [PMCID]
19. Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, Modesitt SC, Lu KH, Geisler JP, Higgins RV, Magtibay PM. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecologic oncology. 2002 Oct 1;87(1):1-7. [DOI:10.1006/gyno.2002.6805] [PMID] [DOI:10.1006/gyno.2002.6805] [PMID]
20. Kalapotharakos G, Högberg T, Bergfeldt K, Borgfeldt C. Long‐term survival in women with borderline ovarian tumors: a population‐based survey of borderline ovarian tumors in Sweden 1960-2007. Acta obstetricia et gynecologica Scandinavica. 2016 Apr;95(4):473-9. [DOI:10.1111/aogs.12846] [PMID] [DOI:10.1111/aogs.12846] [PMID]
21. Novikova EG, Shevchuk AS. Organ-sparing therapy for patients with borderline ovarian tumors. Voprosy onkologii. 2014;60(3):267-73.
22. Vasconcelos I, de Sousa Mendes M. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk. European Journal of Cancer. 2015 Mar 1;51(5):620-31. [DOI:10.1016/j.ejca.2015.01.004] [PMID] [DOI:10.1016/j.ejca.2015.01.004] [PMID]
23. Kato K, Nishikimi K, Tate S, Kiyokawa T, Shozu M. Histopathologic tumor spreading in primary ovarian cancer with modified posterior exenteration. World journal of surgical oncology. 2015 Dec;13(1):230. [DOI:10.1186/s12957-015-0647-x] [PMID] [PMCID] [DOI:10.1186/s12957-015-0647-x] [PMID] [PMCID]
24. Chen R, Zhu T, Yu H, Zhu J, Lu X. Retrospective analysis of the clinical outcomes in 12 recurrent borderline ovarian tumor patients with second fertility-sparing surgery. Zhonghua fu chan ke za zhi. 2014 Apr;49(4):254-9.
25. Ziari K, Izadi Mod N, Kosari F, Sarmadi S. The study of morphologic criteria and prognosis in serous ovarian tumers. JAUMS. 2007; 5(1): 1085-91.

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2020 All Rights Reserved | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.